Skip to main
SEPN
SEPN logo

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Septerna Inc. is advancing its clinical-stage pipeline through its proprietary Native Complex Platform, which focuses on developing novel GPCR therapies across critical therapeutic areas such as endocrinology, immunology and inflammation, and metabolic disease. Management's confidence in executing Phase 1 trials more efficiently, combined with the promising preclinical testing results demonstrating a longer half-life and effective dosing of candidates like SEP-479 in TPTx rat models, supports a favorable outlook on the company's prospects. The potential for improved clinical outcomes and enhanced drug candidate performance positions Septerna favorably within the competitive biotechnology landscape.

Bears say

Septerna Inc is currently in the clinical-stage biotechnology sector, focusing on GPCR oral small molecule drug discovery, yet faces challenges in translating its proprietary Native Complex Platform into successful product candidates. The company's financials may reflect substantial research and development expenditures without guaranteed returns, particularly as the pipeline consists of multiple early-stage candidates that require further validation in the market. Additionally, the concentration of its therapeutic focus in three areas—endocrinology, immunology and inflammation, and metabolic disease—could pose risks if these markets fail to yield viable commercial outcomes.

Septerna Inc (SEPN) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Buy based on their latest research and market trends.

According to 4 analysts, Septerna Inc (SEPN) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.